Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCV3 + peginterferon alfa-2a
- Development stage
- Unknown
- Lead developer
- Fundació Clínic per la Recerca Biomèdica
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intranodal, Subcutaneous
01
Overview
DCV3 + peginterferon alfa-2a is an experimental combination therapy investigated for the treatment of HIV-1 infection. It consists of DCV3, an autologous dendritic cell-based therapeutic vaccine (monocyte-derived dendritic cells pulsed with heat-inactivated autologous HIV-1), and peginterferon alfa-2a, a pegylated formulation of the cytokine interferon alpha-2a. The vaccine component is designed to stimulate an immune response against the patient's specific HIV strain by presenting autologous viral antigens to the immune system. Peginterferon alfa-2a acts as a biologic immunomodulator that binds to the Type I interferon receptor, enhancing the antiviral immune response and potentially reducing the viral reservoir. Clinical trials sponsored by Judit Pich Martínez have evaluated the safety, immunogenicity, and virologic effects of this combination in HIV-1 infected adults on stable antiretroviral therapy (cART).
- Other names
- DCV3 vaccine with PEG-IFNDCV-3 vaccine with PEG-IFNDCV 3 vaccine with PEG-IFNPEG-IFN-α-2a + DCV3Autologous dendritic cell-based therapeutic vaccine with pegylated interferon alpha-2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on DCV3 + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCV3 + peginterferon alfa-2a.